Faster diagnosis and accurate prognosis for rheumatoid arthritis

Important results from the project

All project questions have been fully or partially answered. In addition to achieving its original goals, the project has generated other valuable outcomes. Beyond the commercial development of the rheumatoid arthritis test, it has strengthened the ability to characterize biomarkers in humanized mouse models, providing a deeper understanding of disease mechanisms. Furthermore, the project´s results have created synergy with initiatives exploring therapeutic candidates for rheumatoid arthritis.

Expected long term effects

The project results will guide the test towards a simplified design. The exploration of new application areas has identified aspects not worth pursuing, while simultaneously shaping the commercial development focus for a lead product. Additionally, the project is expected to foster new international collaborations.

Approach and implementation

The project was led by the company and successfully carried out in collaboration with the innovator, healthcare sector, and clinical laboratory. Studies were conducted at the end-user laboratory, and partners explored new applications for the test. Roles and expertise complemented each other well. Milestones were achieved, and the collaboration continues beyond the project´s conclusion.